# Theravance Biopharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Theravance Biopharma, Inc.). ## Overview Theravance Biopharma is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for respiratory and other specialty indications. Its portfolio includes an approved COPD therapy, YUPELRI, and a late-stage investigational program, ampreloxetine, supported through a mix of internal development and collaboration arrangements. ## Products & services • YUPELRI (revefenacin) inhalation solution for COPD • Ampreloxetine, a late-stage investigational therapy for nOH in MSA • Collaboration-based commercialization and royalty interests • Drug development and regulatory advancement of specialty medicines - **Commercial respiratory medicine** (70%) — Approved inhaled therapy sold for maintenance treatment of COPD. - **Collaboration revenue** (25%) — Revenue earned from partnered commercialization and licensing arrangements. - **Licensing revenue** (5%) — Upfront or milestone-based licensing income from partnered assets. - YUPELRI (revefenacin) inhalation solution for COPD - Ampreloxetine, a late-stage investigational therapy for nOH in MSA - Collaboration-based commercialization and royalty interests - Drug development and regulatory advancement of specialty medicines ## Customers Theravance Biopharma sells into the respiratory care market through healthcare providers, physicians, distributors, and third-party payors. Its commercial product is used by COPD patients who need or prefer nebulized maintenance therapy, while its development programs target specialty neurology and autonomic-disorder populations through future prescribing channels. - **COPD patients and prescribers** (primary) — Buy and prescribe YUPELRI for maintenance treatment of COPD, especially where nebulized delivery is preferred. - **Third-party payors** (primary) — Influence access, reimbursement, and formulary placement for YUPELRI and future products. - **Healthcare providers and distributors** (secondary) — Handle prescribing, dispensing, and distribution of the company’s commercial product. - **Pharmaceutical partners** (secondary) — Collaborate on commercialization, milestones, royalties, and licensing arrangements. - **Specialty neurology patients** (emerging) — Potential future users of ampreloxetine if approved for symptomatic nOH in MSA. - Physicians treating COPD patients who need maintenance bronchodilation - Patients who prefer nebulized delivery over handheld inhalers - Third-party payors that determine coverage and reimbursement access - Distributors and healthcare providers in the U.S. pharmaceutical channel - Future prescribers and specialists for nOH in MSA if ampreloxetine is approved ## Geography Theravance Biopharma is headquartered in the United States and its commercial focus is primarily the U.S. COPD market. The company also has economic exposure to global partner commercialization through royalty and milestone arrangements, which can broaden its revenue base beyond direct product sales. - Headquartered in the United States - YUPELRI is commercialized in the U.S. COPD market - Revenue also includes partner-related collaboration and royalty streams - Partner commercialization can create indirect exposure to non-U.S. markets - Geography matters because reimbursement and regulation vary by market ## Strategy The company’s strategy centers on sustaining YUPELRI’s commercial position while advancing ampreloxetine through late-stage development. It also relies on collaboration structures to extend reach, monetize partnered assets, and reduce the capital intensity of building a larger commercial footprint. - **Grow YUPELRI adoption** (short-term) — Commercial revenue depends on physician, patient, and payor acceptance of the COPD product. - **Advance ampreloxetine** (medium-term) — A successful late-stage program could add a new specialty medicine and diversify the portfolio. - **Monetize collaborations and royalties** (medium-term) — Partnered arrangements provide non-dilutive revenue and reduce direct commercialization burden. - Support YUPELRI adoption in the U.S. COPD maintenance market - Advance ampreloxetine through late-stage clinical development - Use collaborations to share development and commercialization risk - Pursue licensing and milestone opportunities from partnered assets - Maintain supply continuity for a single-product commercial base ## Risks Theravance Biopharma is exposed to concentration risk because a large part of its business depends on YUPELRI and on partner execution in commercialization and royalties. Its development pipeline also carries the usual biotechnology risks of clinical failure, regulatory delay, manufacturing dependence, and reimbursement pressure in a highly regulated market. - **Dependence on YUPELRI commercialization** [high] — A meaningful share of the company’s business is tied to one approved COPD product. - **Clinical development failure for ampreloxetine** [high] — Late-stage drug candidates can fail on efficacy, safety, or regulatory grounds. - **Partner dependence** [medium] — Milestones, royalties, and commercialization outcomes depend on third-party partners. - **Manufacturing and supply chain concentration** [high] — The company relies on single suppliers for YUPELRI API, drug product, and warehousing. - **Reimbursement and healthcare regulation** [medium] — Payor coverage, anti-kickback rules, and pricing controls affect market access. - YUPELRI demand may not grow enough to support future revenue - Clinical trials for ampreloxetine may fail or be delayed - Partner execution affects commercialization and royalty income - Single-source API, drug product, and warehousing create supply risk - Reimbursement, pricing, and healthcare regulation can limit uptake ## Accounting The most important accounting issue is revenue recognition across a mixed model of product-related collaboration revenue, licensing revenue, and royalty or milestone receipts. Investors should also watch estimates around contingent liabilities, litigation, tax matters, and any judgments tied to collaboration economics, because these items can materially affect reported results without changing underlying product demand. - **Collaboration and licensing revenue recognition** — Can create uneven quarterly revenue recognition - **Royalty and milestone accounting** — Can cause volatility in reported revenue - **Contingent liabilities and indemnification obligations** — May require accruals or disclosures - **Development asset valuation** — Could affect impairment assessments and balance sheet values - Revenue recognition for collaboration, licensing, and milestone arrangements - Timing of royalty and milestone receipts versus underlying partner sales - Estimates for contingent liabilities, tax matters, and indemnification obligations - Potential impairment or valuation issues for development-stage assets - Quarterly comparability can be affected by milestone timing and partner sales --- *Last updated: 2026-04-29T05:03:39.939299+00:00*